Although a small-scale trial with only 8 patients enrolled, this first-in-human study demonstrated that DOTAP/cholesterol liposomes can be safely administered to patients intravenously and resulted in the uptake of the TUSC2 gene by human primary and metastatic tumors as well as anti-tumor effects [38]. This evidence concerns the gene TUSC2 and metastatic neoplasm.